APO RESEARCH · REPORT
Attention-Deficit Hyperactivity Disorder (ADHD) Medications
Selected research
Industry Research
Attention-Deficit Hyperactivity Disorder (ADHD) Medications Industry Research Report 2026
Market perspective
The global Attention-Deficit Hyperactivity Disorder (ADHD) Medications market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Attention-Deficit Hyperactivity Disorder (ADHD) Medications market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Attention-Deficit Hyperactivity Disorder (ADHD) Medications market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Attention-Deficit Hyperactivity Disorder (ADHD) Medications market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Attention-Deficit Hyperactivity Disorder (ADHD) Medications include The Takeda Pharmaceutical Company Limited, Novartis AG, Eli Lilly and Company, Pfizer Inc., Supernus Pharmaceutical,Inc., purdue Pharma L.P., Neos Therapeutics Inc., Mallinckrodt Pharmaceuticals and Lupin Limited and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Attention-Deficit Hyperactivity Disorder (ADHD) Medications market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Attention-Deficit Hyperactivity Disorder (ADHD) Medications.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market by Company
The Takeda Pharmaceutical Company Limited
Novartis AG
Eli Lilly and Company
Pfizer Inc.
Supernus Pharmaceutical,Inc.
purdue Pharma L.P.
Neos Therapeutics Inc.
Mallinckrodt Pharmaceuticals
Lupin Limited
Johnson & Johnson
Attention-Deficit Hyperactivity Disorder (ADHD) Medications Segment by Type
Stimulants
Non-stimulants
Attention-Deficit Hyperactivity Disorder (ADHD) Medications Segment by Application
Hospital
Clinic
Others
Attention-Deficit Hyperactivity Disorder (ADHD) Medications Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attention-Deficit Hyperactivity Disorder (ADHD) Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Attention-Deficit Hyperactivity Disorder (ADHD) Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attention-Deficit Hyperactivity Disorder (ADHD) Medications.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Attention-Deficit Hyperactivity Disorder (ADHD) Medications companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Stimulants
- Non-stimulants
Applications
- Hospital
- Clinic
- Others
Companies covered
- The Takeda Pharmaceutical Company Limited
- Novartis AG
- Eli Lilly and Company
- Pfizer Inc.
- Supernus Pharmaceutical,Inc.
- purdue Pharma L.P.
- Neos Therapeutics Inc.
- Mallinckrodt Pharmaceuticals
- Lupin Limited
- Johnson & Johnson
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Attention-Deficit Hyperactivity Disorder (ADHD) Medications by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Stimulants
- 2.2.3 Non-stimulants
- 2.3 Attention-Deficit Hyperactivity Disorder (ADHD) Medications by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Breakdown Data by Type
- 3.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Historic Market Size by Type (2021-2026)
- 3.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Forecasted Market Size by Type (2027-2032)
4 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Breakdown Data by Application
- 4.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Historic Market Size by Application (2021-2026)
- 4.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Perspective (2021-2032)
- 5.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Growth Trends by Region
- 5.2.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Historic Market Size by Region (2021-2026)
- 5.2.3 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Forecasted Market Size by Region (2027-2032)
- 5.3 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Dynamics
- 5.3.1 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Industry Trends
- 5.3.2 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Drivers
- 5.3.3 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Challenges
- 5.3.4 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Medications Players by Revenue
- 6.1.1 Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Medications Players by Revenue (2021-2026)
- 6.1.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue Market Share by Players (2021-2026)
- 6.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Attention-Deficit Hyperactivity Disorder (ADHD) Medications Head Office and Area Served
- 6.4 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Players, Product Type & Application
- 6.5 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Manufacturers Established Date
- 6.6 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size (2021-2032)
- 7.2 North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2021-2026)
- 7.4 North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size (2021-2032)
- 8.2 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2021-2026)
- 8.4 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size (2021-2032)
- 9.2 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size (2021-2032)
- 10.2 South America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2021-2026)
- 10.4 South America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size (2021-2032)
- 11.2 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 The Takeda Pharmaceutical Company Limited
- 12.1.1 The Takeda Pharmaceutical Company Limited Company Information
- 12.1.2 The Takeda Pharmaceutical Company Limited Business Overview
- 12.1.3 The Takeda Pharmaceutical Company Limited Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2021-2026)
- 12.1.4 The Takeda Pharmaceutical Company Limited Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
- 12.1.5 The Takeda Pharmaceutical Company Limited Recent Developments
- 12.2 Novartis AG
- 12.2.1 Novartis AG Company Information
- 12.2.2 Novartis AG Business Overview
- 12.2.3 Novartis AG Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2021-2026)
- 12.2.4 Novartis AG Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
- 12.2.5 Novartis AG Recent Developments
- 12.3 Eli Lilly and Company
- 12.3.1 Eli Lilly and Company Company Information
- 12.3.2 Eli Lilly and Company Business Overview
- 12.3.3 Eli Lilly and Company Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2021-2026)
- 12.3.4 Eli Lilly and Company Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
- 12.3.5 Eli Lilly and Company Recent Developments
- 12.4 Pfizer Inc.
- 12.4.1 Pfizer Inc. Company Information
- 12.4.2 Pfizer Inc. Business Overview
- 12.4.3 Pfizer Inc. Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2021-2026)
- 12.4.4 Pfizer Inc. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
- 12.4.5 Pfizer Inc. Recent Developments
- 12.5 Supernus Pharmaceutical,Inc.
- 12.5.1 Supernus Pharmaceutical,Inc. Company Information
- 12.5.2 Supernus Pharmaceutical,Inc. Business Overview
- 12.5.3 Supernus Pharmaceutical,Inc. Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2021-2026)
- 12.5.4 Supernus Pharmaceutical,Inc. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
- 12.5.5 Supernus Pharmaceutical,Inc. Recent Developments
- 12.6 purdue Pharma L.P.
- 12.6.1 purdue Pharma L.P. Company Information
- 12.6.2 purdue Pharma L.P. Business Overview
- 12.6.3 purdue Pharma L.P. Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2021-2026)
- 12.6.4 purdue Pharma L.P. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
- 12.6.5 purdue Pharma L.P. Recent Developments
- 12.7 Neos Therapeutics Inc.
- 12.7.1 Neos Therapeutics Inc. Company Information
- 12.7.2 Neos Therapeutics Inc. Business Overview
- 12.7.3 Neos Therapeutics Inc. Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2021-2026)
- 12.7.4 Neos Therapeutics Inc. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
- 12.7.5 Neos Therapeutics Inc. Recent Developments
- 12.8 Mallinckrodt Pharmaceuticals
- 12.8.1 Mallinckrodt Pharmaceuticals Company Information
- 12.8.2 Mallinckrodt Pharmaceuticals Business Overview
- 12.8.3 Mallinckrodt Pharmaceuticals Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2021-2026)
- 12.8.4 Mallinckrodt Pharmaceuticals Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
- 12.8.5 Mallinckrodt Pharmaceuticals Recent Developments
- 12.9 Lupin Limited
- 12.9.1 Lupin Limited Company Information
- 12.9.2 Lupin Limited Business Overview
- 12.9.3 Lupin Limited Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2021-2026)
- 12.9.4 Lupin Limited Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
- 12.9.5 Lupin Limited Recent Developments
- 12.10 Johnson & Johnson
- 12.10.1 Johnson & Johnson Company Information
- 12.10.2 Johnson & Johnson Business Overview
- 12.10.3 Johnson & Johnson Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2021-2026)
- 12.10.4 Johnson & Johnson Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
- 12.10.5 Johnson & Johnson Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst